MedTrace Logo

A Study of Cardiovascular Events iN Diabetes Plus

NCT05441267 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20000

Last updated 2024-05-08

No results posted yet for this study

Summary

ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide Oral Tablet

Oral semaglutide 14mg daily (option to reduce to 7mg daily)

DRUG

Placebo oral tablet

Placebo oral semaglutide

Sponsors & Collaborators

Principal Investigators

  • David Preiss · University of Oxford

  • Marion Mafham · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-13
Primary Completion
2028-08-17
Completion
2048-08-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05441267 on ClinicalTrials.gov